Table 5.

Waist Circumference and Hemoglobin by Gender, Receipt of Gender-Affirming Treatment (GAT) at Study Entry and Region, Among Natal Males^a

Characteristic	PATS-M Taking GAT	PATS-M not Taking GAT	CIS-M	P Value*
High waist circumference [>102 cm]
Overall	17/46 38%	14/75 19%	937/5001 19%	.006
Within High Income and Latin American regions	17/46 38%	14/57 25%	863/3910 22%	.05
Hemoglobin g/dL: Median (Q1, Q3)
Overall	13.7 (12.9, 14.4)	14.4 (13.7, 15.1)	14.8 (13.9, 15.6)	<.001
Within High Income and Latin American regions	13.7 (12.9, 14.4)	14.3 (13.5, 15.0)	14.8 (14.0, 15.6)	<.001
% with hemoglobin 9 to <11 g/dL
Overall	2.2%	1.3%	0.7%	.2
Within High Income and Latin American regions	2.5%	2.4%	0.4%	.05

Abbreviations: CIS-M, cisgender men; GAT, gender affirming treatmeant; PATS-M, persons identifying across the transgender spectrum among natal males.

^aGAT may include 1 or more of estrogen, progesterone, or antiandrogen (eg, spironolactone).

*P values from χ ² tests among all 3 groups, except % with low hemoglobin, which reflects Fisher’s exact test.

NOTE: All PATS-M taking GAT (n = 46) reside in the High Income and Latin American regions. All PATS-M with high waist circumference (n = 31) also happen to reside in these 2 regions.